-
Synthetic Biology, Genomics & Advanced Therapeutics21 hours agoCellares and GenomeFrontier to assess automated GF-CART01 production
The collaboration, which marks Cellares’ first development project in Asia, will explore adapting GenomeFrontier’s virus-free process to the Cell Shuttle system. It aims to assist GenomeFrontier’s...
-
Regulatory Intelligence & Drug Approvals21 hours agoViatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction. It also applies to narcolepsy with and without cataplexy,...
-
Capital, M&A & Industry Strategy2 days agoGilead and PAHO agree to expedite lenacapavir access for HIV prevention
The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds. The collaboration enables 14 countries,...
-
Capital, M&A & Industry Strategy2 days agoEli Lilly and QurCan sign genetic medicine deal
The companies intend to work together on several research programmes focused on QurCan’s Target-Engineered Responsive Polymer (TERP) polymer-lipid nanoparticle (PLNP) delivery platform development. QurCan uses its...
-
Capital, M&A & Industry Strategy3 days agoCheplapharm to take over 20 medicines and three sites from Sanofi
Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began...
-
Regulatory Intelligence & Drug Approvals3 days agoFDA reduces monitoring time for Amgen’s Imdelltra infusions
The revised guidance is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy. It recommends a monitoring period ranging between six and eight...
-
Synthetic Biology, Genomics & Advanced Therapeutics7 days agoExegenesis Bio and Modalis sign research deal for Duchenne therapy
The agreement involves the use of Modalis’ CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio’s engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181. EMC181 is...
-
Manufacturing, Supply Chain & Infrastructure7 days agoABEC to expand global manufacturing network with new Wilson facility
A ribbon-cutting ceremony to mark the opening is scheduled for 24 September, with company leadership, employees, partners and community leaders expected to attend. According to ABEC,...
-
Capital, M&A & Industry Strategy1 week agoSolstice Oncology secures $225m to drive porustobart’s development for cancer
The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors. Porustobart is a...
-
Capital, M&A & Industry Strategy1 week agoTwoStep Therapeutics secures $62.5m funding to advance TS-104
Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA,...
FDA Approves Fayuvi (rebisufligene etisparvovec-hopf) Gene Therapy for the Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
Novo’s Denecimig Demonstrates Tolerability After Switch from Emicizumab in FRONTIER5 Study of People with Haemophilia A as Published in the Journal of Thrombosis and Haemostasis
Bayer’s Kerendia (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
